Sales of the multiple myeloma drug Revlimid continue to thrive even after patent expiry in Korea.

According to industry sources, Bristol Myers Squibb Korea’s Revlimid (lenalidomide) still boasts its originality with an 80% market share.

As of Q3 2024 (IQVIA), Revelimid's sales were KRW 11.2 billion, significantly outpacing the sales of generics such as Lenaloma (KRW 800 million), Lenalid (KRW 981.1 million), Leblikin (KRW 305.85 million), and Lenaldo (KRW 35.51 million) during the same period.

Revlimid has been used for various blood diseases for nearly 20 years since its approval by the U.S. Food and Drug Administration (FDA) in 2005 and has solidified its positi